Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Blocking IL-6 signaling prevents astrocyte-induced neurodegeneration in an iPSC-based model of Parkinson’s disease
Meritxell Pons-Espinal, Lucas Blasco-Agell, Irene Fernandez-Carasa, Pol Andrés-Benito, Angelique di Domenico, Yvonne Richaud-Patin, Valentina Baruffi, Laura Marruecos, Lluís Espinosa, Alicia Garrido, Eduardo Tolosa, Michael J. Edel, Manel Juan Otero, José Luis Mosquera, Isidre Ferrer, Angel Raya, Antonella Consiglio
Meritxell Pons-Espinal, Lucas Blasco-Agell, Irene Fernandez-Carasa, Pol Andrés-Benito, Angelique di Domenico, Yvonne Richaud-Patin, Valentina Baruffi, Laura Marruecos, Lluís Espinosa, Alicia Garrido, Eduardo Tolosa, Michael J. Edel, Manel Juan Otero, José Luis Mosquera, Isidre Ferrer, Angel Raya, Antonella Consiglio
View: Text | PDF
Research Article Inflammation Neuroscience

Blocking IL-6 signaling prevents astrocyte-induced neurodegeneration in an iPSC-based model of Parkinson’s disease

  • Text
  • PDF
Abstract

Parkinson’s disease (PD) is a neurodegenerative disease associated with progressive death of midbrain dopamine (DAn) neurons in the substantia nigra (SN). Since it has been proposed that patients with PD exhibit an overall proinflammatory state, and since astrocytes are key mediators of the inflammation response in the brain, here we sought to address whether astrocyte-mediated inflammatory signaling could contribute to PD neuropathology. For this purpose, we generated astrocytes from induced pluripotent stem cells (iPSCs) representing patients with PD and healthy controls. Transcriptomic analyses identified a unique inflammatory gene expression signature in PD astrocytes compared with controls. In particular, the proinflammatory cytokine IL-6 was found to be highly expressed and released by PD astrocytes and was found to induce toxicity in DAn. Mechanistically, neuronal cell death was mediated by IL-6 receptor (IL-6R) expressed in human PD neurons, leading to downstream activation of STAT3. Blockage of IL-6R by the addition of the FDA-approved anti–IL-6R antibody, Tocilizumab, prevented PD neuronal death. SN neurons overexpressing IL-6R and reactive astrocytes expressing IL-6 were detected in postmortem brain tissue of patients at early stages of PD. Our findings highlight the potential role of astrocyte-mediated inflammatory signaling in neuronal loss in PD and pave the way for the design of future therapeutics.

Authors

Meritxell Pons-Espinal, Lucas Blasco-Agell, Irene Fernandez-Carasa, Pol Andrés-Benito, Angelique di Domenico, Yvonne Richaud-Patin, Valentina Baruffi, Laura Marruecos, Lluís Espinosa, Alicia Garrido, Eduardo Tolosa, Michael J. Edel, Manel Juan Otero, José Luis Mosquera, Isidre Ferrer, Angel Raya, Antonella Consiglio

×

Figure 3

L2-PD astrocytes induce iPSC-derived DA neuronal degeneration through IL-6/IL-6R signaling.

Options: View larger image (or click on image) Download as PowerPoint
L2-PD astrocytes induce iPSC-derived DA neuronal degeneration through IL...
(A) Schematic representation of the experimental procedure to analyze the effect of astrocyte conditioned medium (ACM) and IL-6 involvement on neuronal survival and degeneration. ACM was collected after 14 days in culture and added to iPSC-derived DAn from both CTL and patients with L2-PD for 1 week. Anti–IL-6R antibody Tocilizumab (10 μg/mL) was added to ACM. (B) Representative ICC images of iPSC-derived CTL (SP11) and L2-PD neurons (SP12) expressing tyrosine hydroxylase (TH, black) treated for 1 week with CTL-ACM, L2-PD ACM and L2-PD ACM + anti–IL-6R antibody. Scale bar: 100 μm. CTL neurons are derived from SP11 iPSC line. L2-PD neurons are derived from SP12, SP06, and SP13 iPSC lines. (C) Percentage of TH+ cells respect to DAPI. (D) Representative ICC images of iPSC-derived CTL and L2-PD neurons staining for TH (black). Scale bar: 20 μm. (E and F) Number of branches and neurite length of CTL and L2-PD TH+ neurons treated for 1 week with ACM. (G) Representative ICC images of DAn (TH, red) expressing IL-6R (green) from CTL (SP11) and L2-PD (SP13) iPSC-derived DAn after 35 days of differentiation. Scale bar: 20 μm. (H) Orthogonal views show colocalization between IL-6R and TH in L2-PD (SP13) DAn. (I) Representative Western blot for IL-6R of iPSC-derived CTL neurons (SP11) and L2-PD neurons (SP12). (J) Quantification of protein IL-6R respect to β-actin. (K) Relative IL-6R mRNA expression from iPSC-derived CTL neurons (SP11 and SP17) and L2-PD neurons (SP12 and SP13). Box-and-whisker plots show median, 25th and 75th percentiles, minimum, and maximum values (n = 3 experiments; 30 neurons per experiment per condition for each line). One-way ANOVA was used with Bonferroni as post hoc (C, E, F). Student t test or Mann-Whitney U test (J and K) for nonparametric conditions were used when only 2 groups were compared. *P < 0.05; **P < 0.01; ***P < 0.001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts